Breast Cancer

CancerNetwork®’s podcast dissected a review article published in the journal ONCOLOGY® on the 21-gene recurrence score in patients with node-positive breast cancer.

ABSTRACT The 21-gene Recurrence Score (RS) assay has been validated as both a prognostic and predictive tool in node-negative (pN0), estrogen receptor–positive (ER+), HER2-negative (HER2–) breast cancer. A large body of evidence supports the clinical utility of the RS in the node positive (pN+) population as well. Retrospective analyses of archived tissue from multiple clinical trials have found the RS to be prognostic in both endocrine therapy (ET)-treated and chemotherapy-treated patients with pN+ disease. Distribution of RS results in pN+ patients have also been consistent with those of pN0 populations. Data from the SWOG 8814 trial and large population-based registries further support the prognostic and potential predictive value of the RS. Specifically, patients with 1 to 3 positive nodes and RS less than 18 derived negligible benefit from adjuvant chemotherapy in these studies. In the prospective West German Study Group PlanB and ADAPT trials, pN+ patients with RS less than 11 and RS ≤25, respectively, who were treated with ET alone experienced excellent outcomes. Finally, 5-year results of the RxPONDER clinical trial randomizing patients with 1 to 3 positive nodes and RS ≤25 to ET alone vs ET plus chemotherapy confirmed an absence of chemotherapy benefit in postmenopausal patients. Clinical practice guidelines support use of the RS in the pN+, ER+/HER2– population, and many institutions have adopted the RS to guide clinical decision-making, resulting in a net reduction of adjuvant chemotherapy use. This review highlights the existing data supporting the prognostic and predictive ability of the RS in pN+ disease, current practice patterns related to RS use in this population, and emerging applications.

The combination of palbociclib and endocrine therapy demonstrated a more favorable safety profile and improved quality of life versus capecitabine among patients with metastatic breast cancer who were resistant to aromatase inhibitors, despite not improving progression-free survival.

Investigators suggested that the results of this study may assist health care providers in personalized therapeutic regimen selections for patients with early-stage breast cancer.

“We’re hearing about other antibody-drug conjugates, other agents in hormone receptor–positive metastatic disease, and the next generation of drugs that we’ll be using to treat our patients.”

Imagio, a diagnostic tool that uses novel technology to provide real-time information on suspicious lesions in the breast, is OK’d by the FDA.

The Breast Cancer Index assay is the only of its kind to be recommended in the National Comprehensive Cancer Network Guidelines for the treatment of breast cancer as being predictive of extended adjuvant endocrine therapy.

Investigators aimed to evaluate additional end points from the phase 3 RxPONDER trial in women with hormone receptor–positive, HER2-negative, lymph node–positive breast cancer.

In this trial, investigators launched RxPONDER, in which 5015 patients with a recurrence score between 0 and 25 were randomized to endocrine therapy alone or chemotherapy followed by endocrine therapy.

Investigators whose work was published in JAMA Network Open found that patients with low mammographic breast density were at higher risk of developing severe lymphedema.

A recent study sought to evaluate the 21-gene Oncotype Dx Recurrence Score in nonmetastatic HR-positive, HER2-negative breast cancer.

The breast cancer expert discussed the latest developments in breast cancer research and what she hopes the next year will offer this patient population.

Among women with early-stage triple-negative breast cancer who received standard adjuvant treatment, low-dose capecitabine maintenance therapy for 1 year resulted in significantly improved disease-free survival rates compared with observation.

Plinabulin in combination with pegfilgrastim reduced the incidence of chemotherapy-induced neutropenia, compared with pegfilgrastim alone, in patients with breast cancer undergoing chemotherapy with docetaxel, doxorubicin, and cyclophosphamide.

The breast medical oncologist and researcher discussed how the addition of chemotherapy to endocrine therapy showed clinical benefit in premenopausal, lymph node-positive, HR-positive, HER2-negative breast cancer.

Research presented at the 2020 SABCS found providers planned to use neoadjuvant endocrine therapy for as little as possible until surgery was available for patients with estrogen receptor positive breast cancer.

The GP2/GM-CSF combination demonstrated a 100% disease-free survival at 5 years for patients with HER2/neu 3–positive disease who received adjuvant trastuzumab.

For women with heavily pretreated, postmenopausal advanced or metastatic estrogen receptor (ER)–positive breast cancer, amcenestrant prompted antitumor activity.

The study found that favorable outcomes after treatment with lapatinib (Tykerb) were demonstrated by early declines in circulating tumor cell counts (CTCs) in patients with metastatic breast cancer who initially had HER2-negative primary tumors but positive HER2 CTCs.

Fewer deaths and improved cumulative incidence of central nervous system recurrences were shown at 8 years of follow-up with adjuvant neratinib (Nerlynx) compared with placebo in patients with early-stage HER2-positive breast cancer following trastuzumab (Herceptin)-based therapy.

Combination treatment with alpelisib (Piqray) and letrozole (Femara) sustained efficacy and did not result in any new safety signals in patients with PIK3CA-mutant HR-positive, HER2-negative advanced breast cancer who received prior treatment with the combination of a CDK4/6 inhibitor and fulvestrant (Faslodex).

Women who survive breast cancer may have more difficulty in becoming pregnant when compared to the general population, and have a risk of preterm labor, but most deliver healthy babies and experience no detrimental effects on their long-term survival.

The combination of oral paclitaxel and encequidar has the potential to be an effective treatment for patients with radiation-associated breast angiosarcoma.

Adhering to a diabetes risk reduction diet improved survival for women with stage 1 to 3 breast cancer compared to women who did not follow this specific diet.